Michael Robert A.'s most recent trade in Abbvie Inc was a trade of 27,186 Common Stock, $0.01 par value done at an average price of $205.0 . Disclosure was reported to the exchange on Feb. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie | Robert A. Michael | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 27,186 | 132,821 (0%) | 0% | 205.0 | 5,573,674 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 83,333 | 83,333 | - | - | Option (Right to Buy) | |
| AbbVie | Robert A. Michael | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 24,732 | 123,377 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 14,454 | 160,007 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 12,030 | 145,553 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 10,146 | 133,523 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | PRES & CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 176.46 per share. | 28 Feb 2024 | 47,319 | 98,645 (0%) | 0% | 176.5 | 8,349,911 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | PRES & CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 178.99 per share. | 28 Feb 2024 | 37,638 | 145,964 (0%) | 0% | 179.0 | 6,736,826 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | PRES & CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 176.44 per share. | 28 Feb 2024 | 21,560 | 145,964 (0%) | 0% | 176.4 | 3,804,046 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | PRES & CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 11,420 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Robert A. Michael | PRES & CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.36 per share. | 28 Feb 2024 | 11,420 | 157,384 (0%) | 0% | 61.4 | 700,731 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | PRES & CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 10,140 | 0 | - | - | Option (Right to Buy) | |
| AbbVie | Robert A. Michael | PRES & CHIEF OPERATING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.86 per share. | 28 Feb 2024 | 10,140 | 167,524 (0%) | 0% | 54.9 | 556,280 | Common Stock, $0.01 par value |
| AbbVie | A. Robert Michael | PRES & CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 59,888 | 59,888 | - | - | Option (Right to Buy) | |
| AbbVie | Michael A. Robert | PRES & CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 49,565 | 148,210 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Michael Robert A. | PRES & CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 13,216 | 161,426 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | A. Robert Michael | PRES & CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 12,030 | 183,602 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | A. Robert Michael | PRES & CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 10,146 | 171,572 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | VICE CHAIRMAN | Payment of exercise price or tax liability using portion of securities received from the company at price $ 154.28 per share. | 28 Feb 2023 | 48,335 | 98,645 (0%) | 0% | 154.3 | 7,457,124 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | VICE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 69,517 | 107,394 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | VICE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 45,577 | 45,577 | - | - | Option (Right to Buy) | |
| AbbVie | Robert A. Michael | VICE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 16,220 | 123,614 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | VICE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 13,218 | 136,832 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | VICE CHAIRMAN | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 10,148 | 146,980 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | Vice Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.54 per share. | 25 Feb 2022 | 34,286 | 80,982 (0%) | 0% | 149.5 | 5,127,128 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | Vice Chairman | Sale of securities on an exchange or to another person at price $ 148.49 per share. | 25 Feb 2022 | 26,937 | 42,113 (0%) | 0% | 148.5 | 3,999,878 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | Vice Chairman | Sale of securities on an exchange or to another person at price $ 147.41 per share. | 25 Feb 2022 | 11,932 | 69,050 (0%) | 0% | 147.4 | 1,758,937 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | Vice Chairman | Sale of securities on an exchange or to another person at price $ 149.06 per share. | 25 Feb 2022 | 4,236 | 37,877 (0%) | 0% | 149.1 | 631,432 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 48,161 | 48,161 | - | - | Option (Right to Buy) | |
| AbbVie | Robert A. Michael | Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 40,749 | 78,626 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 16,220 | 103,703 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 11,565 | 115,268 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | Vice Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 8,857 | 87,483 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 107.74 per share. | 28 Feb 2021 | 14,006 | 37,877 (0%) | 0% | 107.7 | 1,509,006 | Common Stock, $0.01 par value |
| AbbVie | Robert A. Michael | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 65,217 | 65,217 | - | - | Option(right to buy) | |
| AbbVie | Robert A. Michael | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 16,220 | 51,883 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 8,859 | 35,663 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 5,049 | 25,319 (0%) | 0% | 0 | Common Stock, $0.01 par value | |
| AbbVie | Robert A. Michael | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 1,485 | 26,804 (0%) | 0% | 0 | Common Stock, $0.01 par value |